# Catalio Capital Management, LP

> Institutional holdings reported to the SEC as of Q2 2026 on Form 13F. CIK 1958125. Source: https://holderbook.com/funds/1958125-catalio-capital-management-lp/

- Reported value: $532.1M
- Positions: 39
- Weight of the ten largest: 56.7%
- Filed: 2026-08-14

A 13F reports long US equity positions only. Short positions, bonds, foreign listings, private holdings and cash are not visible, so this is not the manager's whole book.

## Holdings

| Security | Ticker | Value | Shares | Weight | Quarters held |
|---|---|---|---|---|---|
| AVALYN PHARMACEUTICALS INC | [AVLN](https://holderbook.com/stocks/AVLN/) | $55.2M | 1,675,830 | 10.4% | 1 |
| JOHNSON & JOHNSON | [JNJ](https://holderbook.com/stocks/JNJ/) | $35.3M | 138,946 | 6.6% | 1 |
| GILEAD SCIENCES INC | [GILD](https://holderbook.com/stocks/GILD/) | $34.0M | 269,309 | 6.4% | 3 |
| BRIDGEBIO PHARMA INC | [BBIO](https://holderbook.com/stocks/BBIO/) | $33.9M | 455,041 | 6.4% | 7 |
| SYNDAX PHARMACEUTICALS INC | [SNDX](https://holderbook.com/stocks/SNDX/) | $26.6M | 1,215,698 | 5.0% | 6 |
| DEFINIUM THERAPEUTICS INC | [DFTX](https://holderbook.com/stocks/DFTX/) | $26.5M | 562,672 | 5.0% | 2 |
| BRISTOL-MYERS SQUIBB CO | [BMY](https://holderbook.com/stocks/BMY/) | $23.8M | 412,961 | 4.5% | 3 |
| PARABILIS MEDICINES INC | [PBLS](https://holderbook.com/stocks/PBLS/) | $22.6M | 824,043 | 4.2% | 1 |
| NATERA INC | [NTRA](https://holderbook.com/stocks/NTRA/) | $22.3M | 82,181 | 4.2% | 5 |
| INCYTE CORP | [INCY](https://holderbook.com/stocks/INCY/) | $21.7M | 191,627 | 4.1% | 2 |
| SEPTERNA INC | [SEPN](https://holderbook.com/stocks/SEPN/) | $18.0M | 536,152 | 3.4% | 7 |
| MINERALYS THERAPEUTICS INC | [MLYS](https://holderbook.com/stocks/MLYS/) | $17.5M | 648,722 | 3.3% | 3 |
| HEARTFLOW INC | [HTFL](https://holderbook.com/stocks/HTFL/) | $17.1M | 583,055 | 3.2% | 3 |
| CORVUS PHARMACEUTICALS INC | [CRVS](https://holderbook.com/stocks/CRVS/) | $16.1M | 1,080,888 | 3.0% | 2 |
| STRUCTURE THERAPEUTICS INC | [GPCR](https://holderbook.com/stocks/GPCR/) | $14.8M | 276,550 | 2.8% | 7 |
| PROTAGONIST THERAPEUTICS INC | [PTGX](https://holderbook.com/stocks/PTGX/) | $13.1M | 106,799 | 2.5% | 1 |
| DISC MEDICINE INC | [IRON](https://holderbook.com/stocks/IRON/) | $11.7M | 159,384 | 2.2% | 5 |
| EDWARDS LIFESCIENCES CORP | [EW](https://holderbook.com/stocks/EW/) | $11.3M | 124,778 | 2.1% | 3 |
| AXSOME THERAPEUTICS INC | [AXSM](https://holderbook.com/stocks/AXSM/) | $10.6M | 43,182 | 2.0% | 1 |
| ULTRAGENYX PHARMACEUTICAL IN | [RARE](https://holderbook.com/stocks/RARE/) | $10.6M | 316,252 | 2.0% | 5 |
| KAILERA THERAPEUTICS INC | [KLRA](https://holderbook.com/stocks/KLRA/) | $10.3M | 468,750 | 1.9% | 1 |
| KARYOPHARM THERAPEUTICS INC | [KPTI](https://holderbook.com/stocks/KPTI/) | $9.2M | 940,855 | 1.7% | 6 |
| ODYSSEY THERAPEUTICS INC | [ODTX](https://holderbook.com/stocks/ODTX/) | $8.6M | 457,839 | 1.6% | 1 |
| ASCENDIS PHARMA A/S | [ASND](https://holderbook.com/stocks/ASND/) | $8.5M | 31,759 | 1.6% | 1 |
| KARDIGAN INC | [KARD](https://holderbook.com/stocks/KARD/) | $7.5M | 312,500 | 1.4% | 1 |
| ELEDON PHARMACEUTICALS INC | [ELDN](https://holderbook.com/stocks/ELDN/) | $6.7M | 1,695,071 | 1.3% | 4 |
| 4D MOLECULAR THERAPEUTICS IN | [FDMT](https://holderbook.com/stocks/FDMT/) | $6.3M | 471,254 | 1.2% | 1 |
| VERADERMICS INC | [MANE](https://holderbook.com/stocks/MANE/) | $5.6M | 45,856 | 1.1% | 2 |
| DYNE THERAPEUTICS INC | [DYN](https://holderbook.com/stocks/DYN/) | $5.4M | 244,929 | 1.0% | 3 |
| FRACTYL HEALTH INC | [GUTS](https://holderbook.com/stocks/GUTS/) | $4.9M | 6,168,749 | 0.9% | 7 |
| IMMUNOCORE HLDGS PLC | [IMCR](https://holderbook.com/stocks/IMCR/) | $4.7M | 148,045 | 0.9% | 2 |
| DIANTHUS THERAPEUTICS INC | [DNTH](https://holderbook.com/stocks/DNTH/) | $3.2M | 32,941 | 0.6% | 7 |
| BRIDGEBIO ONCOLOGY THERAPEUT | [BBOT](https://holderbook.com/stocks/BBOT/) | $2.4M | 318,407 | 0.5% | 1 |
| PROTARA THERAPEUTICS INC | [TARA](https://holderbook.com/stocks/TARA/) | $2.0M | 520,148 | 0.4% | 7 |
| HYPERFINE INC | [HYPR](https://holderbook.com/stocks/HYPR/) | $1.8M | 1,320,041 | 0.3% | 7 |
| ATAIBECKLEY INC | [ATAI](https://holderbook.com/stocks/ATAI/) | $1.0M | 196,858 | 0.2% | 2 |
| METAGENOMI THERAPEUTICS INC | [MGX](https://holderbook.com/stocks/MGX/) | $629.5K | 528,993 | 0.1% | 7 |
| OUTSET MED INC | [OM](https://holderbook.com/stocks/OM/) | $511.0K | 118,279 | 0.1% | 6 |
| FAETH THERAPEUTICS INC | [FTH](https://holderbook.com/stocks/FTH/) | $367.9K | 14,718 | 0.1% | 5 |

## What the disclosed book did

Not the fund's return. This is the change in value of the positions disclosed on Form 13F, had they been left untouched, against SPY over the same quarter ends.

| Quarter | Book | Market | Difference | Priced |
|---|---|---|---|---|
| Q2 2026 | +23.8% | +14.8% | +9.0% | 90% |
| Q1 2026 | -2.5% | -4.6% | +2.2% | 98% |
| Q4 2025 | +25.6% | +2.4% | +23.2% | 100% |
| Q3 2025 | +19.1% | +7.8% | +11.2% | 100% |
| Q2 2025 | +2.7% | +10.5% | -7.8% | 100% |
| Q1 2025 | -8.8% | -4.6% | -4.3% | 100% |

## Quarter by quarter

| Quarter | Value | Positions |
|---|---|---|
| Q2 2026 | $532.1M | 39 |
| Q1 2026 | $478.7M | 41 |
| Q4 2025 | $1.1B | 46 |
| Q3 2025 | $540.9M | 38 |
| Q2 2025 | $476.9M | 40 |
| Q1 2025 | $411.1M | 37 |
| Q4 2024 | $457.1M | 33 |